Zhengye Biotechnology Holding
ZYBT
3 hedge funds and large institutions have $7.19K invested in Zhengye Biotechnology Holding in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.99K |
| 2 |
Morgan Stanley
New York
|
+$214 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $6.93K | +$5.99K | +1,289 | New |
|
|
2
Morgan Stanley
New York
| $247 | +$214 | +46 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $5 | +$5 | +1 | New |
|
ZYBT Hedge Fund Activity: Q1 2025 in Review
3 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in Zhengye Biotechnology Holding (ZYBT) for Q1 2025, worth a combined $7.19K.
Buyers outnumbered sellers: 3 funds opened new ZYBT positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $5.99K.
- 3 institutional investors held Zhengye Biotechnology Holding (ZYBT) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $7.19K of Zhengye Biotechnology Holding stock for Q1 2025.
- 3 funds opened new Zhengye Biotechnology Holding positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest Zhengye Biotechnology Holding buyer in Q1 2025 was UBS Group, an estimated $5.99K added.
Based on aggregated 13F filings for Q1 2025.